| CWIAX | JORAX | CWIAX / JORAX | |
| Total Expense Ratio | 0.78 | 1.02 | 76% |
| Annual Report Gross Expense Ratio | 0.78 | 1.02 | 76% |
| Fund Existence | 24 years | 16 years | - |
| Gain YTD | 23.026 | 18.222 | 126% |
| Front Load | 4% | 6% | 61% |
| Min. Initial Investment | 250 | 2500 | 10% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 142B | 3.12B | 4,545% |
| Annual Yield % from dividends | 1.35 | 0.76 | 177% |
| Returns for 1 year | 13.02 | 3.75 | 347% |
| Returns for 3 years | 51.59 | 30.22 | 171% |
| Returns for 5 years | 44.50 | 23.70 | 188% |
| Returns for 10 years | 104.34 | 74.38 | 140% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTCX | 30.22 | 0.71 | +2.41% |
| Fidelity Advisor Biotechnology C | |||
| AIHHX | 7.37 | 0.08 | +1.10% |
| Aristotle Small/Mid Cap Equity I-2 | |||
| BAFWX | 57.52 | 0.29 | +0.51% |
| Brown Advisory Sustainable Growth I | |||
| CAPAX | 9.35 | 0.04 | +0.43% |
| Federated Hermes Capital Income A | |||
| SCRUX | 12.13 | 0.02 | +0.17% |
| Invesco Income Advantage U.S. Fund R | |||